DDIT3 and diffuse large B-cell lymphoma: Since the GCB subtype of advanced-stage DLBCL has a relatively good prognosis (5-year OS of 74%)36 (UpToDate 4, https://www.uptodate.com/contents/prognosis-of-diffuse-large-b-cell-lymphoma), R-CHOP (6 cycles; 21 days between each cycle) is still its standard therapy (UpToDate 5, https://www.uptodate.com/contents/initial-treatment-of-advanced-stage-diffuse-large-b-cell-lymphoma).